Lecture presentation - TMA Department Sites
... Use clear IV solutions Use an infusion device/IV pump Infuse agent slowly to avoid dangerous cardiovascular effects • Monitor cardiac rhythm ...
... Use clear IV solutions Use an infusion device/IV pump Infuse agent slowly to avoid dangerous cardiovascular effects • Monitor cardiac rhythm ...
Naloxone fails to produce conditioned place aversion in
... regulating the `hedonic status' of the organism. The failure of NLX to induce aversion in MOR3/3 mice implies that NLX exerts its aversive e¡ect by blocking tonic activity of endogenous opioid ligands acting solely at the MOR since the total number and distribution of the DOR and U-opioid receptors ...
... regulating the `hedonic status' of the organism. The failure of NLX to induce aversion in MOR3/3 mice implies that NLX exerts its aversive e¡ect by blocking tonic activity of endogenous opioid ligands acting solely at the MOR since the total number and distribution of the DOR and U-opioid receptors ...
HYPOTHALAMIC AND PITUITARY HORMONES Assist Professor
... Prolactin: is a peptide hormone similar in structure to GH, and is also secreted by the anterior pituitary. Its secretion is inhibited by dopamine acting. Its primary function is to stimulate and maintain lactation. In addition, it decreases sexual drive and reproductive function. On the other hand ...
... Prolactin: is a peptide hormone similar in structure to GH, and is also secreted by the anterior pituitary. Its secretion is inhibited by dopamine acting. Its primary function is to stimulate and maintain lactation. In addition, it decreases sexual drive and reproductive function. On the other hand ...
Uncoupling between noradrenergic and serotonergic neurons as a
... To identify the a1-adrenergic receptor subtype involved in this phenomenon, we used mice knockout for the a1badrenergic receptor subtype (a1b-AR KO) that were given by Susanna Cotecchia from the University of Lausanne (Switzerland) [14]. These KO mice have no apparent phenotype changes except a decr ...
... To identify the a1-adrenergic receptor subtype involved in this phenomenon, we used mice knockout for the a1badrenergic receptor subtype (a1b-AR KO) that were given by Susanna Cotecchia from the University of Lausanne (Switzerland) [14]. These KO mice have no apparent phenotype changes except a decr ...
Subtype-selective GABAA receptor mimetics—novel
... SL651498 appear favorable [25, 26]. It is, however, not yet clear whether these compounds would be suitable for human pain studies. Possible caveats include the rather low intrinsic activity of TPA023 [27] and remaining activity at α1 subunits of SL651498 [21] which might cause significant sedation ...
... SL651498 appear favorable [25, 26]. It is, however, not yet clear whether these compounds would be suitable for human pain studies. Possible caveats include the rather low intrinsic activity of TPA023 [27] and remaining activity at α1 subunits of SL651498 [21] which might cause significant sedation ...
Reciprocal Regulation of Agonist and Inverse Agonist Signaling
... obtained for SNC-80 and bremazocine, the two tested compounds producing detectable [35S]GTP␥S binding in control conditions. As shown in Fig. 1B, the EC50 value for bremazocine was shifted to the left by a factor of 24, whereas that of SNC-80 remained unchanged. Results from cAMP accumulation assays ...
... obtained for SNC-80 and bremazocine, the two tested compounds producing detectable [35S]GTP␥S binding in control conditions. As shown in Fig. 1B, the EC50 value for bremazocine was shifted to the left by a factor of 24, whereas that of SNC-80 remained unchanged. Results from cAMP accumulation assays ...
Thromboxane Receptors Antagonists and/or Synthase Inhibitors
... Western countries. Several clinical conditions are characterized by increased incidence of cardiovascular events and enhanced thromboxane (TX)-dependent platelet activation. Enhanced TX generation may be explained by mechanisms relatively insensitive to aspirin. More potent drugs possibly overcoming ...
... Western countries. Several clinical conditions are characterized by increased incidence of cardiovascular events and enhanced thromboxane (TX)-dependent platelet activation. Enhanced TX generation may be explained by mechanisms relatively insensitive to aspirin. More potent drugs possibly overcoming ...
Pharmacological treatment of schizophrenia–a review of progress
... improvement in schizophrenia symptoms compared with placebo and comparable efficacy to risperidone.25 In the same study ITI-007 fared better compared with risperidone for negative and extrapyramidal symptoms. As of June 2015 Intra Cellular Therapies was recruiting subjects for a 6-week phase III con ...
... improvement in schizophrenia symptoms compared with placebo and comparable efficacy to risperidone.25 In the same study ITI-007 fared better compared with risperidone for negative and extrapyramidal symptoms. As of June 2015 Intra Cellular Therapies was recruiting subjects for a 6-week phase III con ...
IDENTIFICATION OF DUAL AGONISTIC NOVEL LIGANDS FOR INSULIN RECEPTOR AND... THROUGH MOLECULAR DOCKING
... elevations in postprandial blood glucose3 in which it adapts some definite mechanism. Biguanides, sulphonylureas and thiozolidinediones became available for treatment of type- 2 diabetes and have been effective hypoglycemic agents. Insulin injections are used to manage type-1 diabetes. However they ...
... elevations in postprandial blood glucose3 in which it adapts some definite mechanism. Biguanides, sulphonylureas and thiozolidinediones became available for treatment of type- 2 diabetes and have been effective hypoglycemic agents. Insulin injections are used to manage type-1 diabetes. However they ...
Body Temperature and Analgesic Effects of Selective Mu and Kappa
... basis of findings such as these, we hypothesized that the hyperthermic response to opioids is mediated by the mu receptor and the hypothermic response is mediated by the kappa receptor (Geller et al., 1982; Geller et al., 1986; Adler et al., 1988). However, it was not known whether the same effects ...
... basis of findings such as these, we hypothesized that the hyperthermic response to opioids is mediated by the mu receptor and the hypothermic response is mediated by the kappa receptor (Geller et al., 1982; Geller et al., 1986; Adler et al., 1988). However, it was not known whether the same effects ...
Adverse Reactions to Fluoroquinolones. An Overview on
... or GABAB receptor sites [32,44,87,92]. As previously suggested, the structural similarities of fluoroquinolones to KYNA or other similar compounds which are endogenous ligands of the glutamate receptor might suggest an interaction of quinolones with ligand-gated glutamate receptors [100]. In agreeme ...
... or GABAB receptor sites [32,44,87,92]. As previously suggested, the structural similarities of fluoroquinolones to KYNA or other similar compounds which are endogenous ligands of the glutamate receptor might suggest an interaction of quinolones with ligand-gated glutamate receptors [100]. In agreeme ...
Gastrointestinal Disorders: Nausea in Adults
... regarding QT interval prolongation and severe cardiac arrhythmias, use iv droperidol only for the prevention or treatment of postoperative nausea and vomiting (PONV) when other treatments are ineffective or inappropriate and at the lowest effective dose. Promethazine has similar efficacy but is mor ...
... regarding QT interval prolongation and severe cardiac arrhythmias, use iv droperidol only for the prevention or treatment of postoperative nausea and vomiting (PONV) when other treatments are ineffective or inappropriate and at the lowest effective dose. Promethazine has similar efficacy but is mor ...
Opiates
... Complete analgesia may not be produced in some patients under certain conditions owing to insufficient doses being given: here, an increase in the dose may be prejudiced by the side effects of the opioids. The large numbers of opioid receptors in areas of the brainstem such as the solitary tract and ad ...
... Complete analgesia may not be produced in some patients under certain conditions owing to insufficient doses being given: here, an increase in the dose may be prejudiced by the side effects of the opioids. The large numbers of opioid receptors in areas of the brainstem such as the solitary tract and ad ...
Novartis Award for Hypertension Research Reconsidering the Roles
... Twenty years ago, 2 laboratories14,15 proposed that epithelial aldosterone selectivity was conferred by the coexpression of MR and the enzyme 11-hydroxysteroid dehydrogenase (11HSD2), which converts cortisol and corticosterone to their MR-inactive 11-keto congeners cortisone and 11-dehydrocorticos ...
... Twenty years ago, 2 laboratories14,15 proposed that epithelial aldosterone selectivity was conferred by the coexpression of MR and the enzyme 11-hydroxysteroid dehydrogenase (11HSD2), which converts cortisol and corticosterone to their MR-inactive 11-keto congeners cortisone and 11-dehydrocorticos ...
5-Hydroxytryptamine2C Receptor Contribution to m
... m-CPP and FG-7142-Induced Behavioral Changes Are Blocked by SB 242084. Acute administration of both m-CPP and FG-7142 significantly reduced the total amount of time spent in social interaction compared with vehicleinjected animals (Fig. 1A; ANOVA: F(2,15) ⫽ 130.9, p ⬍ 0.0001). The doses used were ch ...
... m-CPP and FG-7142-Induced Behavioral Changes Are Blocked by SB 242084. Acute administration of both m-CPP and FG-7142 significantly reduced the total amount of time spent in social interaction compared with vehicleinjected animals (Fig. 1A; ANOVA: F(2,15) ⫽ 130.9, p ⬍ 0.0001). The doses used were ch ...
Optimising the Use of p-Adrenoceptor Antagonists in Coronary
... than patients receiving only the proarrhythmic active agents encainide and flecainide. Similar favourable trends for patients on P-adrenoceptor antagonist therapy with regard to survival from arrhythmic death or cardiac arrest were also found. These findings support the belief that P-adrenoceptor an ...
... than patients receiving only the proarrhythmic active agents encainide and flecainide. Similar favourable trends for patients on P-adrenoceptor antagonist therapy with regard to survival from arrhythmic death or cardiac arrest were also found. These findings support the belief that P-adrenoceptor an ...
Ganglionic Blocking Drugs and Nicotine
... Although a number of drugs possessing ganglionic blocking properties have been developed, at the present time they are rarely used clinically. Other drugs, such as curare, are not employed as ganglionic blocking agents, although they block ganglionic nicotinic receptors, especially at high doses. Th ...
... Although a number of drugs possessing ganglionic blocking properties have been developed, at the present time they are rarely used clinically. Other drugs, such as curare, are not employed as ganglionic blocking agents, although they block ganglionic nicotinic receptors, especially at high doses. Th ...
Reinforcing Effects of Psychostimulants in Humans Are Associated
... and Wise, 1977; Richardson et al., 1994; Self et al., 1996), its relevance in humans subjects, for whom its rewarding effects are associated with the subjective perception of pleasure or “high” (Fischman and Foltin, 1991), has not been investigated. It is also of importance to assess the role of DA ...
... and Wise, 1977; Richardson et al., 1994; Self et al., 1996), its relevance in humans subjects, for whom its rewarding effects are associated with the subjective perception of pleasure or “high” (Fischman and Foltin, 1991), has not been investigated. It is also of importance to assess the role of DA ...
![Nefazodone in the rat: mimicry and antagonism of [À]-DOM](http://s1.studyres.com/store/data/007839591_1-ac381daefe7f911d421bf0a90c9e2846-300x300.png)
Nefazodone in the rat: mimicry and antagonism of [À]-DOM
... 1). This biphasic effect of nefazodone was not predictable based on reports of nefazodone being a potent 5-HT2A antagonist (Taylor et al., 1995; Davis et al., 1997). More specifically, as the dose of nefazodone administered intraperitoneally is increased, we observe an elevation in [ ]DOM appropriat ...
... 1). This biphasic effect of nefazodone was not predictable based on reports of nefazodone being a potent 5-HT2A antagonist (Taylor et al., 1995; Davis et al., 1997). More specifically, as the dose of nefazodone administered intraperitoneally is increased, we observe an elevation in [ ]DOM appropriat ...
Can`t I Just Take a Pill For It?
... airway muscles and reduces apneas. In June 2003 at the 2003 Associated Professional Sleep Societies (APSS) Conference in Chicago*, Carley and Radulovacki reported results of their study on 12 human subjects who had used mirtazapine to reduce sleep apnea. The subjects were given either a placebo or o ...
... airway muscles and reduces apneas. In June 2003 at the 2003 Associated Professional Sleep Societies (APSS) Conference in Chicago*, Carley and Radulovacki reported results of their study on 12 human subjects who had used mirtazapine to reduce sleep apnea. The subjects were given either a placebo or o ...
the PDF
... administration of doses up to 600 mg resulted in local plasma levels of 5–20 ng/g. In comparison, oral racemic baclofen at the very high dose of 100 mg gave concentrations of <3 ng/g in CSF. An additional benefit was a major reduction in the unwanted side effects with high doses required for systemi ...
... administration of doses up to 600 mg resulted in local plasma levels of 5–20 ng/g. In comparison, oral racemic baclofen at the very high dose of 100 mg gave concentrations of <3 ng/g in CSF. An additional benefit was a major reduction in the unwanted side effects with high doses required for systemi ...
酸枣仁油软胶囊的新药开发研究
... receptor molecules or unlimited drug molecules, the drug-receptor binding is limited. →Emax 2) Specific binding (lock-key) 3) Reversible binding 4) High potency (affinity) →low KD (dose) 5) Competitive binding 2 drugs binding to same receptor. a antagonist is competitive with an endogenous agonist ...
... receptor molecules or unlimited drug molecules, the drug-receptor binding is limited. →Emax 2) Specific binding (lock-key) 3) Reversible binding 4) High potency (affinity) →low KD (dose) 5) Competitive binding 2 drugs binding to same receptor. a antagonist is competitive with an endogenous agonist ...
Laurate Biosensors Image Brain Neurotransmitters In Vivo: Can an Antihypertensive Medication Alter Psychostimulant Behavior?
... open-field behaviors and (c) ketanserin inhibits 5-HT release in NAc and open-field behaviors produced by caffeine, but, surprisingly, acts to increase DA release in NAc. Importantly, the latter effect may be a possible adverse effect of the moderate dose of caffeine in hypertensive patients. Thus, ...
... open-field behaviors and (c) ketanserin inhibits 5-HT release in NAc and open-field behaviors produced by caffeine, but, surprisingly, acts to increase DA release in NAc. Importantly, the latter effect may be a possible adverse effect of the moderate dose of caffeine in hypertensive patients. Thus, ...
Product Monograph
... MAXALT® has been associated with transient chest and/or neck pain and tightness which may resemble angina pectoris. Following the use of other 5-HT 1 agonists, in rare cases these symptoms have been identified as being the likely result of coronary vasospasm or myocardial ischemia. Rare cases of ser ...
... MAXALT® has been associated with transient chest and/or neck pain and tightness which may resemble angina pectoris. Following the use of other 5-HT 1 agonists, in rare cases these symptoms have been identified as being the likely result of coronary vasospasm or myocardial ischemia. Rare cases of ser ...
5-HT3 antagonist
The 5-HT3 antagonists, informally known as ""setrons"", are a class of drugs that act as receptor antagonists at the 5-HT3 receptor, a subtype of serotonin receptor found in terminals of the vagus nerve and in certain areas of the brain.With the notable exception of alosetron and cilansetron, which are used in the treatment of irritable bowel syndrome, all 5-HT3 antagonists are antiemetics, used in the prevention and treatment of nausea and vomiting. They are particularly effective in controlling the nausea and vomiting produced by cancer chemotherapy and are considered the gold standard for this purpose.The 5-HT3 antagonists may be identified by the suffix –setron, and are classified under code A04AA of the WHO's Anatomical Therapeutic Chemical Classification System.